GERN
NASDAQ · Biotechnology
Geron Corp
$1.51
-0.03 (-1.95%)
Open$1.50
Previous Close$1.54
Day High$1.53
Day Low$1.48
52W High$2.66
52W Low$1.04
Volume—
Avg Volume16.92M
Market Cap1.20B
P/E Ratio—
EPS$-0.12
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+1,158.9% upside
Current
$1.51
$1.51
Target
$19.01
$19.01
$12.94
$19.01 avg
$24.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 77.75M | 153.95M | 141.15M |
| Net Income | -176,233,236 | -36,660,557 | -32,364,939 |
| Profit Margin | -226.7% | -23.8% | -22.9% |
| EBITDA | -176,820,245 | -44,322,691 | -40,350,825 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 |
| Rev Growth | +281.2% | +15.1% | +6.9% |
| Debt/Equity | 0.87 | 0.42 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |